Thus, it is important to focus on cancer type-specific deregulated pathways in therapy development, such as the unique SPCA2-Orai1 or SK3-Orai1 co-regulation in breast cancer or the specific role of Orai3 in various cancer types. This evidence concerns the gene KCNN3 and breast carcinoma.